Evidence map›Paper›PMID 29381702›Full record

ArticlePLoS medicine2018

Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study.

European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord, Ali Judd, Elizabeth Chappell, Anna Turkova, Sophie Le Coeur, Antoni Noguera-Julian, Tessa Goetghebuer, Katja Doerholt, Luisa Galli, Dasja Pajkrt and 23 more

Abstract read
In one paragraph

Article in PLoS medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Viral Suppression, Viral Failure, and Safety Outcomes in Children and Adolescents With HIV on Dolutegravir in Europe and Thailand.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord
Ali JuddMRC Clinical Trials Unit, University College London (UCL), London, United Kingdom.ORCID 0000-0003-3176-5295
Elizabeth ChappellMRC Clinical Trials Unit, University College London (UCL), London, United Kingdom.ORCID 0000-0003-1053-6434
Anna TurkovaMRC Clinical Trials Unit, University College London (UCL), London, United Kingdom.ORCID 0000-0002-7008-4145
Sophie Le CoeurInstitut National d'Etude Demographique (INED), Mortality, Health and Epidemiology Unit, Paris, France.
Antoni Noguera-JulianUnitat d'Infectologia, Servei de Pediatria, Hospital Sant Joan de Deu, Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0001-7485-0583
Tessa GoetghebuerHopital St Pierre, Brussels, Belgium.ORCID 0000-0002-8809-1394
Katja DoerholtSt George's Healthcare NHS Trust, London, United Kingdom.
Luisa GalliDepartment of Health Sciences, Pediatric Unit, University of Florence, Florence, Italy.
Dasja PajkrtDepartment of Pediatric Infectious Diseases, Emma Children's Hospital, Academic Medical Center, Amsterdam, the Netherlands.ORCID 0000-0002-5232-8206
Laura MarquesCentro Hospitalar do Porto, Porto, Portugal.
Intira J CollinsMRC Clinical Trials Unit, University College London (UCL), London, United Kingdom.
Diana M GibbMRC Clinical Trials Unit, University College London (UCL), London, United Kingdom.ORCID 0000-0002-9738-5490
Maria Isabel González TomeHospital Doce de Octubre, Madrid, Spain.
Marisa NavarroHospital General Universitario "Gregorio Marañón", Madrid, Spain.ORCID 0000-0002-1234-6936
Josiane WarszawskiInstitut National de la Santé et de la Recherche (INSERM), Paris, France.
Christoph KönigsUniversity Hospital Frankfurt, Department of Paediatrics, Goethe University, Frankfurt, Germany.
Vana SpoulouUniversity of Athens Medical School, Athens, Greece.
Filipa PrataHospital de Santa Maria, Lisbon, Portugal.
Elena ChiappiniDepartment of Health Sciences, Pediatric Unit, University of Florence, Florence, Italy.
Lars NaverKarolinska University Hospital, Stockholm, Sweden.ORCID 0000-0001-6027-0211
Carlo GiaquintoPaediatric European Network for the Treatment of AIDS (PENTA), Padova, Italy.
Claire ThorneUCL Great Ormond Street Institute of Child Health, London, United Kingdom.
Magdalena MarczynskaMedical University of Warsaw, Hospital of Infectious Diseases, Warsaw, Poland.
Liubov OkhonskaiaRepublican Hospital of Infectious Diseases, St Petersburg, Russia.
Klara Posfay-BarbeHopitaux Universitaires de Genève, Genève, Switzerland.
Pradthana OunchanumChiang Rai Prachanukroh Hospital, Chiang Rai, Thailand.
Pornchai TechakunakornDepartment of Pediatrics, Phayao Provincial Hospital, Phayao, Thailand.
Galina KiselevaShupyk National Medical Academy of Postgraduate Education, Kiev, Ukraine.
Ruslan MalyutaPerinatal Prevention of AIDS Initiative, Odessa, Ukraine.
Alla VolokhaShupyk National Medical Academy of Postgraduate Education, Kiev, Ukraine.
Luminita EneVictor Babes Hospital, Bucharest, Romania.
Ruth GoodallMRC Clinical Trials Unit, University College London (UCL), London, United Kingdom.ORCID 0000-0003-0622-5035

Funding

Medical Research Council MC_UU_12023/17Medical Research Council MC_UU_12023/26
6 · The paper itself

Abstract

backgroundPublished estimates of mortality and progression to AIDS as children with HIV approach adulthood are limited. We describe rates and risk factors for death and AIDS-defining events in children and adolescents after initiation of combination antiretroviral therapy (cART) in 17 middle- and high-income countries, including some in Western and Central Europe (W&CE), Eastern Europe (Russia and Ukraine), and Thailand. METHODS AND

findingsChildren with perinatal HIV aged <18 years initiating cART were followed until their 21st birthday, transfer to adult care, death, loss to follow-up, or last visit up until 31 December 2013. Rates of death and first AIDS-defining events were calculated. Baseline and time-updated risk factors for early/late (≤/>6 months of cART) death and progression to AIDS were assessed. Of 3,526 children included, 32% were from the United Kingdom or Ireland, 30% from elsewhere in W&CE, 18% from Russia or Ukraine, and 20% from Thailand. At cART initiation, median age was 5.2 (IQR 1.4-9.3) years; 35% of children aged <5 years had a CD4 lymphocyte percentage <15% in 1997-2003, which fell to 15% of children in 2011 onwards (p < 0.001). Similarly, 53% and 18% of children ≥5 years had a CD4 count <200 cells/mm3 in 1997-2003 and in 2011 onwards, respectively (p < 0.001). Median follow-up was 5.6 (2.9-8.7) years. Of 94 deaths and 237 first AIDS-defining events, 43 (46%) and 100 (42%) were within 6 months of initiating cART, respectively. Multivariable predictors of early death were: being in the first year of life; residence in Russia, Ukraine, or Thailand; AIDS at cART start; initiating cART on a nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen; severe immune suppression; and low BMI-for-age z-score. Current severe immune suppression, low current BMI-for-age z-score, and current viral load >400 c/mL predicted late death. Predictors of early and late progression to AIDS were similar. Study limitations include incomplete recording of US Centers for Disease Control (CDC) disease stage B events and serious adverse events in some countries; events that were distributed over a long time period, and that we lacked power to analyse trends in patterns and causes of death over time.

conclusionsIn our study, 3,526 children and adolescents with perinatal HIV infection initiated antiretroviral therapy (ART) in countries in Europe and Thailand. We observed that over 40% of deaths occurred ≤6 months after cART initiation. Greater early mortality risk in infants, as compared to older children, and in Russia, Ukraine, or Thailand as compared to W&CE, raises concern. Current severe immune suppression, being underweight, and unsuppressed viral load were associated with a higher risk of death at >6 months after initiation of cART.

Indexed as

Disease ProgressionAcquired Immunodeficiency SyndromeAdolescentAnti-Retroviral AgentsChildChild, PreschoolCohort StudiesDrug Therapy, CombinationEuropeHIV InfectionsHumansInfantInfant, NewbornRisk FactorsThailandAnti-Retroviral Agents

Identifiers

PMID29381702
PMCPMC5790238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.